What's new in the Learning Zone?
Visit the asthma resources section to view footage from the Novartis-sponsored symposia at ERS 2022: “A triple approach to shifting the asthma paradigm: inhaled therapy, digital technology and the environment” and “Asthma and beyond: Anti-IgE continues to play a major role”. Also, learn about the environmental impact of inhalers and how this can be a factor in treatment decision making once efficacy and safety have been considered in the new sustainability section.
Please take part in this survey exploring sex and gender differences in asthma management – it should take no more than 10 minutes to complete. Your input would help tremendously in understanding the impact of sex or gender on asthma management, and will ultimately help improve patients’ lives. Survey produced by Novartis Pharma AG. This survey is anonymous, your personal information will not be collected.
Inhaled Management of Asthma
Find out the latest updates on inhaled medications (including their place in the 2020 GINA strategy), targets for treatment and the importance of inhaler devices in drug delivery.
Find out about the environmental impact of respiratory treatments, how improved asthma control can help the planet and how we can all act to reduce our impact.
Resources for Asthma
Click here to find the latest educational resources for asthma
An overview of asthma and COPD, including symptoms and diagnosis.
Independently-led ERS 2020
Explore this section for the latest updates from ERS International Congress 2020 Virtual, including hot topic articles and KOL interviews.
Digital Health Solutions
Discover the latest information on novel digital health solutions in respiratory care
Developed by EPG Health for Medthority in collaboration with Novartis Pharma AG, with content provided by Novartis Pharma AG. The views presented in the videos are those of the presenters and not necessarily those of the industry sponsor, Novartis Pharma AG. Any data on non-Novartis products are based on publicly available information at the time of content update. Prescribing information may vary depending on local health authority approval in each country. Before prescribing any product, always refer to the SmPC or product information approved in your local country. AGI HCP survey: MLR ID: 172821 FUSE ID: 126140. Landing Page: FUSE ID: 256119.